May 2026 Research Update

This month added a clearer picture of how varied treatment can be across the myositis family, especially in people with more complex disease. In routine care, centers reported using a mix of standard immune-suppressing medicines and newer options, with safety described as generally acceptable. Separately, a single rare genetic case showed that resetting the immune system through a stem cell transplant can coincide with long-term improvement, but this cannot be assumed for typical polymyositis. [1] [2]

In a Polish hospital cohort of 35 people with idiopathic inflammatory myopathies, polymyositis was uncommon (1 case), and lung involvement was frequent across the group, including interstitial lung disease in 60%. The report described common use of steroids and other immune medicines, and it also documented use of rituximab, JAK inhibitors, anifrolumab, sirolimus, and nintedanib in selected patients, with no new major safety pattern highlighted beyond expected treatment-related problems in an ill, hospitalized population. [1]

A separate case report focused on a child with biallelic ITCH deficiency (a rare immune disorder) who developed juvenile polymyositis and other autoimmune problems. After an allogeneic hematopoietic stem cell transplant, the patient reached durable remission by 3 years, came off immune-suppressing medicines, and regained ventilator independence, showing what may be possible in very specific genetic situations. [2]

For patients, these reports mainly add context rather than changing what is known to work for polymyositis today. The cohort study shows that in real clinics, people with myositis may receive many different immune-targeting medicines depending on organ involvement (especially lung disease) and how severe the illness is, but it did not test which approach is best. The transplant case is important as proof that rare, gene-driven autoimmune myositis can behave differently, yet it remains an individual experience and does not predict outcomes for most people with polymyositis.

This month, several larger studies looked at what tends to go wrong over time in people with idiopathic inflammatory myopathies, including polymyositis. Across studies, the picture was consistent that outcomes vary by subtype, and that infections and cancers are major concerns in these conditions. Rather than pointing to one new predictor, these studies helped clarify which patient groups were reported to face higher risks in real-world data. [3] [4] [5] [6]

A meta-analysis pooling 14,548 people with myositis reported that infections occurred in about 24%, most often in the respiratory tract. Higher reported infection risk clustered with anti-MDA5 positivity, rapidly progressive lung disease, dermatomyositis, and stronger immune-suppressing treatment exposures, while the polymyositis phenotype was linked to lower infection risk in the combined data. [3]

Two cohorts focused on longer-term survival patterns and showed that myositis subtype and cancer history matter. In a hospital-based cohort of 225 patients, dermatomyositis had higher reported mortality risk than other subtypes, and having a malignancy was linked to a much higher risk of death, while joint involvement and non-dermatomyositis subtypes were linked to lower risk. [5]

A nationwide Swedish registry study followed 2,346 adults with myositis and tracked second primary cancers after a first cancer that occurred at or after myositis. Among 326 who developed a first cancer, 37 developed a second primary cancer, with higher reported risk in men and in those with a prior cancer history; the study also reported substantial mortality after a second cancer, especially in dermatomyositis. [4]

Another multicenter Italian study of 228 people reported that males had higher measured disease activity, and that anti-MDA5 positivity and greater accumulated damage were linked to higher activity. It also reported that dermatomyositis and polymyositis were linked to lower activity scores in their dataset, underscoring that the label alone does not always match how active the illness is at a given moment. [6]

For patients and caregivers, these studies mainly help set expectations about what doctors and researchers pay attention to over time: infections, cancer, and differences between myositis subtypes. The infection meta-analysis may matter now because it clarifies which features were repeatedly seen in people who developed infections, but it does not prove that any one factor causes infection in an individual person. The cancer and survival studies may matter over time because they describe who was more likely to have later cancers or worse survival in large datasets, but they cannot predict what will happen to a specific person and do not explain why the differences occur.

One study this month suggested that the lungs may show subtle changes in blood vessels even before interstitial lung disease (lung scarring) is diagnosed. In people with polymyositis or dermatomyositis who did not have interstitial lung disease, quantitative CT measurements showed lower intrapulmonary vascular volume compared with healthy controls. This points to the possibility of early, less visible lung involvement, although it is not yet clear how it relates to symptoms or long-term outcomes. [7]

The study included 71 PM/DM patients without interstitial lung disease and 71 matched controls, and the reduction in vascular volume was seen across all lung lobes. The imaging measures also tracked with several blood inflammation markers, linking the CT findings to immune activity in the body, but the study did not include breathing tests or detailed treatment information that could explain how these changes affect daily life. [7]

For patients, this is mainly an early research signal about what might be happening in the lungs before standard scans show interstitial lung disease. It does not mean that everyone with polymyositis has lung blood vessel problems, and it does not establish what should be done differently, because the study did not test interventions or connect these measurements to future outcomes. What it adds is a possible explanation for why some people may have lung-related issues earlier than expected, which future studies may confirm or refine.

This month included several case-based reports showing that people with muscle inflammation conditions can have problems in other organs, and that these conditions can sometimes present in unusual ways. Taken together, these reports emphasize that swallowing problems, severe joint disease, and overlap with other autoimmune diseases can be part of the lived experience for some people, especially when immune suppression is involved. Because these are small numbers, they illustrate possibilities rather than giving average risks. [8] [9] [10]

One polymyositis case described painful swallowing due to a large upper esophageal ulcer in a patient on methotrexate and prednisone, where biopsy did not find infection or cancer and symptoms improved with a proton pump inhibitor. This report highlights that not all ulcers in immunosuppressed people are infectious, but careful testing was needed to rule out infections first. [8]

A separate case report described a patient with anti-synthetase syndrome who developed severe knee arthritis and deformity and underwent total knee replacement, reflecting how disabling large-joint disease can become in some people. Another small pediatric series described 6 children with lupus complicated by myositis, where muscle symptoms improved with treatment in all, but one child had a recurrence after an inappropriate taper that improved after more intensive treatment. [9] [10]

For patients and caregivers, these case-based reports may matter most as awareness: people with myositis and related conditions can have problems outside the muscles, such as a swallowing-tube ulcer in one person on immune-suppressing treatment or severe disease in major joints, and myositis can overlap with other autoimmune diseases. They do not tell how common these problems are, and they cannot show which treatments work best, because they describe only one patient or a very small group. What they offer is a clearer list of real-world situations researchers are documenting, which can guide what future larger studies should measure.

Several exploratory studies this month looked at possible mechanisms and risk signals rather than day-to-day patient outcomes. Together, they expand the list of biological pathways and medication exposures that researchers are connecting to myositis, but they are not direct evidence that a new treatment works or that a drug will cause myositis in any one person. The common thread is early-stage mapping: identifying what to study next in humans. [11] [12] [13]

In a mouse model of myositis-associated interstitial lung disease, nerandomilast (a PDE4B inhibitor) reduced lung inflammation and fibrosis and lowered lab measures linked to immune overactivity, including markers of NETs (web-like DNA released by immune cells). The same study reported higher PDE4B expression in a very small sample of human lung tissue from dermatomyositis-associated lung disease, which supports PDE4B as a research target but does not show benefit in people. [11]

A safety database analysis using FAERS reported strong reporting signals for inflammatory myositis across multiple immune checkpoint inhibitors, with dermatomyositis signals generally stronger than polymyositis signals. Because spontaneous reports can be biased and do not prove cause and effect, this mainly serves as a warning sign for researchers and regulators about where to look more carefully. [12]

A genetic cross-trait study reported shared genetic architecture between idiopathic inflammatory myopathies (including polymyositis) and several B-cell lymphoma subtypes, identifying multiple new risk loci for lymphoma when conditioning on myositis genetics. This does not mean myositis causes lymphoma or vice versa, but it suggests some shared immune pathways that may help explain why these conditions can cluster in certain people. [13]

For patients, these studies are mainly about future directions. The mouse study points to a pathway that could someday lead to new lung-focused treatments, but it is not ready to predict patient results. The checkpoint inhibitor analysis may matter now mostly as context for people who developed myositis while on cancer immunotherapy, since it shows this has been reported across many agents, while still leaving uncertainty about true frequency and individual risk. The genetics study may matter later by helping explain shared immune roots between myositis and some blood cancers, but it does not provide individual risk estimates or a test to use in routine care.